Lipigon Pharmaceuticals AB (FRA:9RP) Total Equity: €0.73 Mil (As of Dec. 2025)


What is Lipigon Pharmaceuticals AB Total Equity?

Lipigon Pharmaceuticals AB FRA:9RP Total Equity is €0.73 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Lipigon Pharmaceuticals AB's total equity for the quarter that ended in Dec. 2025 was €0.73 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Lipigon Pharmaceuticals AB Total Equity Historical Data

* Premium members only.

The historical data trend for Lipigon Pharmaceuticals AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipigon Pharmaceuticals AB Total Equity Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 2.24 0.35 2.54 0.68 0.73

Lipigon Pharmaceuticals AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 2.67 2.04 1.37 0.73

Lipigon Pharmaceuticals AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Lipigon Pharmaceuticals AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1.078-0.351
=0.73

Lipigon Pharmaceuticals AB's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1.078-0.351
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €0.73 Mil mean?
Lipigon Pharmaceuticals AB (FRA:9RP) has a Total Equity of €0.73 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Lipigon Pharmaceuticals AB and its competitors.
Is Lipigon Pharmaceuticals AB's Total Equity too high?
Lipigon Pharmaceuticals AB's current Total Equity is €0.73 Mil.
How does Lipigon Pharmaceuticals AB's Total Equity compare to VRTX and REGN?
Lipigon Pharmaceuticals AB's Total Equity of €0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Lipigon Pharmaceuticals AB and its competitors. Lipigon Pharmaceuticals AB's current Total Equity is €0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipigon Pharmaceuticals AB stock overvalued right now?
Lipigon Pharmaceuticals AB (FRA:9RP) has a current Total Equity of €0.73 Mil. The current Total Equity is €0.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Lipigon Pharmaceuticals AB (FRA:9RP), the current Total Equity is €0.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipigon Pharmaceuticals AB Business Description

Address Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.